Rapamycin: FK506's fraternal twin or distant cousin?
Rapamycin (RPM) is the latest in a series of new bacterial-derived immunosuppressants. Here, Randall Morris compares and contrasts the mechanism of action and immune-modulating potential of RPM with the structurally-similar FK506.
Morris
R E
RE
Dept. of Cardiothoracic Surgery, Stanford University Medical School, CA94305-5247.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000494:pharmacology; D000935:Antifungal Agents / Q000737:chemistry* / Q000494:pharmacology; D001402:B-Lymphocytes / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000737:chemistry* / Q000494:pharmacology; D011090:Polyenes / Q000737:chemistry* / Q000494:pharmacology; D020123:Sirolimus; D013601:T-Lymphocytes / Q000187:drug effects; D016559:Tacrolimus
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D011090:Polyenes; D020123:Sirolimus; D016559:Tacrolimus